Company Overview and News
Greetings, and welcome to Regency Centers’ Second Quarter 2018 Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.
REG EQIT EQY
TEL-AVIV, Israel, July 26, 2018 (GLOBE NEWSWIRE) -- Gazit Globe (NYSE/TSX/TASE: GZT), a leading global real estate company focused on the ownership, management and development of retail and mixed use properties in urban markets, announced that on July 25, 2018, wholly-owned subsidiaries of the Company sold 5.6 million shares of common stock of Regency Centers Corporation (NYSE:REG) (“Regency”), for approximately $61.
REG FCR.DB.H FCR.DB.I FCR.DB.J GZT DTK EQIT FCRGF GZT FCR FCR.DB.E EQY
Good afternoon, and welcome to DDR Reports Second Quarter 2018 Operating Results Conference Call. All participants will be in listen-only mode. [Operator Instructions] After today's presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note this event is being recorded.
DDR BGFLX DDR.WI EQIT EQY
Regency Centers Corporation’s (REG - Free Report) focus on building a premium portfolio of grocery-anchored shopping centers, aimed at driving dependable traffic, bodes well. However, the company’s growing development and redevelopment pipeline exposes it to various risks such as rising construction costs, entitlement delays and lease-ups.
REG LB TCO EQIT MU KIM MAC EQY
Ladies and gentlemen, thank you for standing by. Welcome to the Gazit-Globe First Quarter 2018 Results Conference Call. At this time, all participants are in a listen-only mode. There will be a presentation followed by question-and-answer session. I advise you that this conference is being recorded today, Tuesday, May 29, 2018. The presentation that will be used in today's call and the financial statements can be found on Gazit-Globe's Web site at www.
FCAP URBN EQIT EQY
Given the turbulence, I decided my time was better spent searching for new ideas and that, as a recently launched long-biased fund, the letter should address the selloff.
DDR TLSTF EQIT EQY
At this time all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.
REG EQIT EQY
Regency Centers Corporation’s (REG - Free Report) first-quarter 2018 funds from operations (FFO) per share of 96 cents surpassed the Zacks Consensus Estimate of 94 cents. Further, results compared favorably with 27 cents reported in the year-ago quarter. However, results in the year-ago period included one-time merger-related costs of 55 cents per share. The company’s quarterly results reflect growth in same-property net operating income (NOI).
REG LRCX TWX PF TWC EQIT FRT ESS HST EQY
Regency Centers Corp. (REG - Free Report) is slated to report first-quarter 2018 results on Apr 30, after the market closes. Both its revenues and funds from operations (FFO) per share are expected to experience year-over-year growth. Last quarter, this Jacksonville, FL-based retail real estate investment trust (REIT) delivered in-line FFO per share. Results reflected growth in same-property net operating income (NOI) and strong leasing activity during the quarter.
REG TCO EQIT SPG MS RLJ EQY
2018-08-13 - Asif
Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...
2018-08-13 - Asif
Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...
2018-08-13 - Asif
Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...